Cambridge, MA-based Alnylam Pharmaceuticals, a leading developer of drugs using RNA interference technology, said today it lost an oral argument that it should be granted a particular patent in Europe from its Kreutzer-Limmer patent estate. The final decision on the patent, known as ‘945, is still subject to further appeal, Alnylam said in a statement. Still, the company’s shares (NASDAQ: [[ticker:ALNY]]) fell 10 percent to $20.70 at 2:50 pm Eastern time.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
